ARTICLE | Finance
Specialty Pearl
Vatera leads $69M round for COPD play Pearl Therapeutics
November 1, 2010 7:00 AM UTC
Specialty pharma-focused venture firm Vatera Healthcare Partners invested in its fourth portfolio company last month, leading a $69 million series C round for respiratory disease company Pearl Therapeutics Inc.
Vatera was formed in 2007 by Michael Jaharis after he cashed out of specialty pharma company Kos Pharmaceuticals Inc., which he founded. Abbott Laboratories (NYSE:ABT) bought Kos for about $3.7 billion in late 2006...